Close-up laboratory-related material illustrating the development context for ibogaine-based medicines

Public-record program index

Development Status Tracker

An evergreen view of investigational ibogaine, noribogaine, and analogue programs: who is developing them, what is publicly identified, and how the evidence behind a stated stage is classified.

Current public status, not a forecast

Investigational programsMolecule and formulationDated public milestonesEvidence classification Investigational programsMolecule and formulationDated public milestonesEvidence classification

01 / Scope

A record of what has been made public.

This tracker follows developers working toward approvable ibogaine-based medicines, including noribogaine and related analogue candidates. It separates a company’s named molecule or formulation from the development stage that can be supported by a dated public source.

For a broader orientation to who makes ibogaine and how producer roles differ, start with the main topic overview. This page is narrower: it tracks investigational development programs rather than treatment provision, product availability, or outcomes.

Stage labels follow public descriptions rather than inference. The U.S. Food and Drug Administration explains that drug development moves through distinct research and review steps, including investigational new drug work and clinical investigation, in its clinical research overview.

02 / Program ledger

Programs with a public development trail.

Each entry pairs a developer and candidate with the most recent milestone that can be tied to a public record. A listed stage does not establish efficacy, safety, approval, manufacturing scale, or future availability.

Developer

atai Life Sciences / Beckley Psytech

Molecule / formulation

BPL-003, described by the developer as an intranasal mebufotenin program rather than an ibogaine or noribogaine candidate.

Development stage

Clinical development; tracker relevance is comparative, as a non-ibogaine psychedelic medicine program.

Most recent public milestone / evidence

Dated company communications and clinical-study records are used where they identify a specific study event. This tracker does not treat a press statement alone as regulatory approval.

Developer

Delix Therapeutics

Molecule / formulation

DLX-001 and other non-hallucinogenic psychoplastogen candidates; public materials describe an analogue-development approach, not commercial ibogaine production.

Development stage

Preclinical public description for the named program set.

Most recent public milestone / evidence

Company materials and peer-reviewed scientific literature provide the applicable evidence category when they identify compound status or preclinical research.

Developer

MindMed

Molecule / formulation

MM402, publicly described as an ibogaine derivative program intended to retain selected properties while avoiding features associated with ibogaine.

Development stage

Preclinical public description.

Most recent public milestone / evidence

Company public materials are the supporting status source unless a trial registry, regulatory filing, preprint, or peer-reviewed paper provides a more specific dated update.

03 / Evidence threshold

The status label is only as strong as the record behind it.

The tracker gives the highest practical weight to a dated clinical registry entry, regulatory document, or peer-reviewed paper that directly identifies the candidate and event. Company releases may document milestones, but are categorized as company-supplied evidence unless independently reflected in a registry or filing.

For U.S. studies, ClinicalTrials.gov is a useful public registry for checking whether a study record identifies an intervention, sponsor, recruitment status, and dates. Registry information can change; the tracker records the status available in the cited public record rather than projecting a next step.

“Investigational” identifies development status, not an approved medicine, clinical recommendation, or conclusion about benefit or risk.

Laboratory setting associated with investigating ibogaine-based medicine development

04 / Method note

How status is categorized.

The tracker uses a conservative, evidence-first method. A program is included only when a developer, study record, paper, or other identifiable public source names both an organization and an ibogaine-related, noribogaine-related, or analogue candidate. For more context on the site’s working approach, see the independent information principles behind this resource.

01Preclinical is used where public material identifies laboratory, animal, formulation, or other nonclinical development without a confirmed human trial record for that candidate.
02Phase 1, 2, or 3 is used only when a public source explicitly states that phase or a registry record supports it.
03Regulatory submission is reserved for a stated filing or review event, not a general expression of development intent.
04Evidence type records whether status rests on a company release, registry entry, filing, preprint, or peer-reviewed publication.

Updates should replace or qualify a prior entry when newer public evidence is more specific. The terminology around ibogaine’s chemical and historical context does not itself establish that a particular derivative, formulation, or program shares the same development status.

05 / Regulatory considerations

Hurdles that shape public development updates.

Why do manufacturing controls matter?

Drug-development programs need a reliable way to identify, make, test, and control the candidate used in studies. The FDA’s drug manufacturing quality information describes the importance of systems intended to help ensure medicines meet quality standards. A public program mention does not disclose the full manufacturing package needed for review.

Why are cardiac safety endpoints frequently discussed?

Ibogaine-related development is often discussed alongside cardiac assessment because public scientific and regulatory materials identify cardiac electrophysiology as a relevant area of evaluation. This tracker records whether a source names a safety assessment; it does not interpret an assessment as a safety conclusion.

What makes a milestone usable in this tracker?

A usable milestone identifies a candidate, a developer or sponsor, a dated event, and a source type. Undated promotional language, generalized pipeline graphics, and claims without a clearly named molecule are not enough to move a stage label.

Does a listed program mean a medicine is approved?

No. A program in this tracker is an investigational development record. Readers comparing entities and roles can use the site’s manufacturer landscape overview alongside these entries, while keeping approval status separate from public development activity.